Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 4/20 | 0.40 |
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14244845 | 0.98 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL11883049 | 0.98 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL11589764 | 0.98 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL8627810 | 0.98 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL14245075 | 0.98 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL8681098 | 0.98 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL1920702 | 0.98 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL1920829 | 0.98 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL417141 | 0.92 | CA12 (0.56) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL11239445 | 0.89 | MGLL (0.52) | CA12CA1CA9CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0052842-B1 | N,N-DIARYL CARBAMOYL FLUORIDES, PROCESS FOR PREPARING THEM AND THEIR USE IN THE PREPARATION OF UREAS, AND THE UREAS OBTAINED THEREBY | BAYER AG (DE) | 1985-09-18 | — | — | EP | claimed |
| EP-2537839-B1 | B-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING B-DIHYDROFURAN DERIVING COMPOUND OR B-TETRAHYDROFURAN DERIVING COMPOUND, B -GLYCOSIDE COMPOUND, METHOD FOR PRODUCING B-GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2016-12-14 | — | — | EP | disclosed |
| US-9212174-B2 | Certain β-dihydrofuran derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| EP-2537839-A1 | B-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING B-DIHYDROFURAN DERIVING COMPOUND OR B-TETRAHYDROFURAN DERIVING COMPOUND, B -GLYCOSIDE COMPOUND, METHOD FOR PRODUCING B-GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120322995-A1 | beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-12-20 | — | — | US | disclosed |
| US-5843983-A | Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| WO-1995000498-A1 | N,N-DIACYLPIPERAZINES | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| US-5348955-A | Angiotensis II antagonists | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| US-5344830-A | Anitinflammatory, cardiovascular, analgesic, central nervous system | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| WO-1994013646-A1 | N,N-DIACYLPIPERAZINE TACHYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| US-5292726-A | N,N-diacylpiperazines | MERCK & CO., INC. (US) | 1994-03-08 | — | — | US | disclosed |
| WO-1992020661-A1 | N, N-DIACYLPIPERAZINES | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| US-4101571-A | REACTING SULFAMIC ACIDS WITH PHOSGENE | BASF AKTIENGESELLSCHAFT (DE) | 1978-07-18 | — | — | US | disclosed |
| US-4080360-A | LACTAM DERIVATIVES | BASF AKTIENGESELLSCHAFT (DT) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322995-A1 | beta-DIHYDROFURAN DERIVING COMPOUND, METHOD FOR PRODUCING beta-DIHYDROFURAN DERIVING COMPOUND OR beta-TETRAHYDROFURAN DERIVING COMPOUND, beta-GLYCOSIDE COMPOUND, METHOD FOR PRODUCING beta GLYCOSIDE COMPOUND, AND METHOD FOR PRODUCING 4'-ETHYNYL D4T AND ANALOGUE COMPOUNDS THEREOF | DHPS, B4GALT1, STT3A | CA12 929/4885CA1 1826/4885CA9 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.